Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06273150 · ClinicalTrials.gov registry record
Dentatorubral-pallidoluysian Atrophy Natural History and Biomarkers Study
A clinical trial of Dentatorubral-Pallidoluysian Atrophy, sponsored by University College, London.
- Recruiting
- Registry status
- 225
- Enrollment target
- 3
- Study locations
NCT06273150: Recruiting study of Dentatorubral-Pallidoluysian Atrophy, sponsored by University College, London.
NCT06273150 is a study of Dentatorubral-Pallidoluysian Atrophy that is actively recruiting participants, run by University College, London. The registered enrollment target is 225 participants. The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06273150, a study of Dentatorubral-Pallidoluysian Atrophy, is actively recruiting participants, sponsored by University College, London.
- RECRUITING
- Registry status
- 225 participants
- Enrollment target
- 3
- Study locations
Study Summary
DRPLA Natural History and Biomarkers Study (DRPLA NHBS) is a prospective observational study that will lay the foundation for clinical trials in DRPLA. The aims of this project are: * To characterize the natural history of DRPLA in both juvenile- and adult-onset patients and study different modalities of biomarkers in this condition. * To identify genetic factors and biomarkers that could predict disease progression. * To provide a platform to support the design and conduct of clinical trials. This study has three arms: 1. Adult Participants: this arm of the study will require participants to be 16 years old or over to participate. 2. Pediatric Participants: this arm of the study will require participants to be under 16 years old to participate. 3. Remote Participants: patients that cannot or do not wish to travel to one of the study sites can participate in this arm of the study, irrespective of their age. Participants will have an annual visit for three years (baseline visit and two follow-up visits, three visits in total). Subjects who complete the whole protocol will be assessed on two consecutive days to reduce patient burden. This project will allow for a better understanding of DRPLA and its course, and therefore allow for future clinical trials on this condition to be more precisely and effectively conducted.
Conditions Studied
Interventions
- OTHER Positive genetic test for pathological expansion in ATN1
Study Locations (3)
New York
- NYU Grossman School of Medicine - New York
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Other
- University College London - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2022-05-01 |
| Est. Completion | 2026-04 |
What NCT06273150 shows while recruiting
NCT06273150 is an observational study that tracks outcomes without assigning an intervention. The registered 225 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Dentatorubral-Pallidoluysian Atrophy appearing as the primary indexed condition, and to 1 intervention - of which Positive genetic test for pathological expansion in ATN1 is the first listed.
NCT06273150 reports a single indexed study location in New York, North Carolina, Other.
Frequently Asked Questions
What is clinical trial NCT06273150 about?
NCT06273150 is a clinical study titled "Dentatorubral-pallidoluysian Atrophy Natural History and Biomarkers Study". DRPLA Natural History and Biomarkers Study (DRPLA NHBS) is a prospective observational study that will lay the foundation for clinical trials in DRPLA. The aims of this project are: * To characterize the natural history of DRPLA in both juvenile- and adult-onset patients and study different modalit...
What is the current status of trial NCT06273150?
This trial is currently recruiting. The enrollment target is 225 participants. The study started on 2022-05-01. Estimated completion is 2026-04.
What conditions does trial NCT06273150 study?
This clinical trial studies the following conditions: Dentatorubral-Pallidoluysian Atrophy.
What interventions are being tested in trial NCT06273150?
The interventions under investigation include: Positive genetic test for pathological expansion in ATN1 (OTHER).
Who is sponsoring clinical trial NCT06273150?
This trial is sponsored by University College, London, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06273150 being conducted?
This trial has 3 study locations across New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dentatorubral-Pallidoluysian Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03955445 · 225 participants · Phase 3
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
- NCT04054310 · 225 participants · NA
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- NCT04480554 · 225 participants · Phase 2
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
- NCT04888104 · 225 participants
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI